Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report
商品番号 : SMB-88135
| 出版社 | Grand View Research |
| 出版年月 | 2025年8月 |
| ページ数 | 150 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 5,950 |
| 種別 | 英文調査報告書 |
関節リウマチ治療薬市場 – 分子（医薬品、バイオ医薬品）、販売チャネル別（処方薬、一般用医薬品）、地域、セグメント別予測による市場規模、成長と動向分析レポート 2025-2033年
世界の関節リウマチ治療薬市場規模は、2024年には257億6,000万米ドルに達すると推定され、2025年から2033年にかけて5.56%のCAGRで成長し、2033年には414億2,000万米ドルに達すると予測されています。関節リウマチ（RA）に対する革新的な治療薬の導入は、市場の成長を促進する上で重要な役割を果たしています。
アムジェン社、ファイザー社、ジェネンテック社、ノバルティス社といった大手製薬企業による、シルテゾ、ヒリモズ、アムゲビタ、エレルジ、アブソラ、リツキシマブといった新規バイオシミラーの発売は、関節リウマチ（RA）治療環境を大きく変革しました。例えば、2024年5月、ベーリンガーインゲルハイム社は、米国食品医薬品局（FDA）が、関節リウマチ、クローン病、潰瘍性大腸炎、乾癬、乾癬性関節炎、化膿性汗腺炎、強直性脊椎炎、中等度から重度の尋常性乾癬、非感染性ぶどう膜炎など、複数の慢性炎症性疾患の治療薬として、ヒュミラの互換バイオシミラーであるシルテゾ（アダリムマブ-adbm）の高濃度クエン酸フリー製剤を承認したと発表しました。
同様の展開として、ノバルティスAGは2023年1月、サンド社のクエン酸フリー高濃度製剤（HCF）「ヒリモズ」（アダリムマブ）について、欧州医薬品庁（CHMP）のヒト用医薬品委員会（CHMP）から販売承認を取得しました。この承認は、関節リウマチ（RA）、ぶどう膜炎、潰瘍性大腸炎、尋常性乾癬を含む、先行薬の全適応症に適用されます。これらの次世代バイオ医薬品およびバイオシミラーは、関節痛や炎症の原因となる特定の免疫系分子または受容体に作用するように設計されており、治療成績の向上をもたらします。このような標的を絞った効果的な治療法への需要の高まりは、RAに対するバイオ医薬品治療のさらなる進歩を促進すると期待されます。
近年、RAの治療戦略は、疾患の寛解を誘導できる新しい分子へと移行しています。この進化は、RAの根本的メカニズムへの理解の深化に端を発し、標的を絞った生物学的および合成疾患修飾性抗リウマチ薬（DMARD）の開発につながっています。第一選択治療には依然として低分子DMARD、コルチコステロイド、鎮痛剤、非ステロイド性抗炎症薬（NSAID）が含まれますが、これらの選択肢は主に疾患の進行を遅らせ、炎症を抑えるものであり、疾患を治癒させるものではありません。さらに、胃腸潰瘍、免疫抑制、骨粗鬆症、吐き気、血球減少症、疲労、発疹、肝障害、乾癬、感染症リスクの増加など、顕著な副作用を引き起こす可能性があります。
Rheumatoid Arthritis Therapeutics Market Summary
The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.
The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company’s interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.
In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Sandoz’s citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.
In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA’s underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.
Rheumatoid Arthritis Therapeutics Market Report Scope
| Report Attribute | Details |
| Market size value in 2025 | USD 26.86 billion |
| Revenue forecast in 2033 | USD 41.42 billion |
| Growth rate | CAGR of 5.56% from 2025 to 2033 |
| Base year for estimation | 2024 |
| Historical data | 2021 – 2023 |
| Forecast period | 2025 – 2033 |
| Quantitative units | Revenue in USD million/billion, and CAGR from 2025 to 2033 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, trends |
| Segments covered | Molecule, sales channel, region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
| Key company profiled | AbbVie, Inc.; Boehringer Ingelheim International GmbH; Novartis AG; Regeneron Pharmaceuticals Inc.; Pfizer, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; UCB S.A.; Johnson & Johnson Services, Inc.; Amgen, Inc.; Lilly (Eli Lilly and Company). |
| Customization scope | Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Global Rheumatoid Arthritis Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:
- Molecule Outlook (Revenue, USD Million, 2021 – 2033)
- Pharmaceuticals
o NSAIDs
o Analgesics
o DMARDs
o Glucocorticoids
- Biopharmaceuticals
o Biologics
o TNF-α antagonists
o T-cell inhibitors
o CD20 antigen
o JAK inhibitors
o Anti-IL6 biologics
o Biosimilars
o CD20 antigen
o TNF-α antagonists
- Sales Channel Outlook (Revenue, USD Million, 2021 – 2033)
- Prescription
- Over-the-Counter (OTC)
- Regional Outlook (Revenue, USD Million, 2021 – 2033)
- North America
o U.S.
o Canada
o Mexico
- Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
- Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
- Latin America
o Brazil
o Argentina
- Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule
1.2.2. Sales Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Rheumatoid Arthritis Therapeutics Market: Molecule Business Analysis
4.1. Molecule Market Share, 2024 & 2033
4.2. Molecule Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2021 to 2033 (USD Million)
4.4. Pharmaceuticals
4.4.1. Pharmaceuticals Market, 2021 – 2033 (USD Million)
4.4.2. NSAIDs
4.4.2.1. NSAIDs Market, 2021 – 2033 (USD Million)
4.4.3. Analgesics
4.4.3.1. Analgesics Market, 2021 – 2033 (USD Million)
4.4.4. DMARDs
4.4.4.1. DMARDs Market, 2021 – 2033 (USD Million)
4.4.5. Glucocorticoids
4.4.5.1. Glucocorticoids Market, 2021 – 2033 (USD Million)
4.5. Biopharmaceuticals
4.5.1. Biopharmaceuticals Market, 2021 – 2033 (USD Million)
4.5.2. Biologics
4.5.2.1. Biologics Market, 2021 – 2033 (USD Million)
4.5.2.2. TNF-α antagonists
4.5.2.2.1. TNF-α antagonists Market, 2021 – 2033 (USD Million)
4.5.2.3. T-cell inhibitors
4.5.2.3.1. T-cell inhibitors Market, 2021 – 2033 (USD Million)
4.5.2.4. CD20 antigen
4.5.2.4.1. CD20 antigen Market, 2021 – 2033 (USD Million)
4.5.2.5. JAK inhibitors
4.5.2.5.1. JAK inhibitors Market, 2021 – 2033 (USD Million)
4.5.2.6. Anti-IL6 biologics
4.5.2.6.1. Anti-IL6 biologics Market, 2021 – 2033 (USD Million)
4.5.3. Biosimilars
4.5.3.1. Biosimilars Market, 2021 – 2033 (USD Million)
4.5.3.2. CD20 antigen
4.5.3.2.1. CD20 antigen Market, 2021 – 2033 (USD Million)
4.5.3.3. TNF-α antagonists
4.5.3.3.1. TNF-α antagonists Market, 2021 – 2033 (USD Million)
Chapter 5. Rheumatoid Arthritis Therapeutics Market: Sales Channel Business Analysis
5.1. Sales Channel Market Share, 2024 & 2033
5.2. Sales Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
5.4. Prescription
5.4.1. Prescription Market, 2021 – 2033 (USD Million)
5.5. Over-the-Counter (OTC)
5.5.1. Over-the-Counter (OTC) Market, 2021 – 2033 (USD Million)
Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, By Country, 2021 – 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5. Europe
6.5.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. AbbVie, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Molecule Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Boehringer Ingelheim International GmbH
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Molecule Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Novartis AG
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Molecule Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Regeneron Pharmaceuticals Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Molecule Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Pfizer, Inc.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Molecule Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Bristol-Myers Squibb Company
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Molecule Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. F. Hoffmann-La Roche Ltd.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Molecule Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. UCB S.A.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Molecule Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Johnson & Johnson Services, Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Molecule Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Amgen, Inc.
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Molecule Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Lilly (Eli Lilly and Company)
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Molecule Benchmarking
7.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 4 Global rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 5 North America rheumatoid arthritis therapeutics market, by region, 2021 – 2033 (USD Million)
Table 6 North America rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 7 North America rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 8 U.S. rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 9 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 10 Canada rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 11 Canada rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 12 Mexico rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 13 Mexico rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 14 Europe rheumatoid arthritis therapeutics market, by country, 2021 – 2033 (USD Million)
Table 15 Europe rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 16 Europe rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 17 UK rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 18 UK rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 19 Germany rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 20 Germany rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 21 France rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 22 France rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 23 Italy rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 24 Italy rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 25 Spain rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 26 Spain rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 27 Norway rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 28 Norway rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 29 Sweden rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 30 Sweden rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 31 Denmark rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 32 Denmark rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 33 Asia Pacific rheumatoid arthritis therapeutics market, by country, 2021 – 2033 (USD Million)
Table 34 Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 35 Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 36 Japan rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 37 Japan rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 38 China rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 39 China rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 40 India rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 41 India rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 42 Australia rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 43 Australia rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 44 South Korea rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 45 South Korea rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 46 Thailand rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 47 Thailand rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 48 Latin America rheumatoid arthritis therapeutics market, by country, 2021 – 2033 (USD Million)
Table 49 Latin America rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 50 Latin America rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 51 Brazil rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 52 Brazil rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 53 Argentina rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 54 Argentina rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 55 Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2021 – 2033 (USD Million)
Table 56 Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 57 Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 58 South Africa rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 59 South Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 60 Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 61 Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 62 UAE rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 63 UAE rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
Table 64 Kuwait rheumatoid arthritis therapeutics market, by molecule, 2021 – 2033 (USD Million)
Table 65 Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2021 – 2033 (USD Million)
List of Figures
Fig. 1 Rheumatoid arthritis therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and molecule outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Rheumatoid arthritis therapeutics market dynamics
Fig. 12 Rheumatoid arthritis therapeutics market: Porter’s five forces analysis
Fig. 13 Rheumatoid arthritis therapeutics market: PESTLE analysis
Fig. 14 Molecule market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 15 Biopharmaceuticals market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 16 Biologics market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 17 TNF-α antagonists market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 18 T-cell inhibitors market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 19 CD20 antigen market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 20 JAK inhibitors market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 21 Anti-IL6 biologics market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 22 Biosimilars market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 23 CD20 antigen market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 24 TNF-α antagonists market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 25 Pharmaceuticals market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 26 NSAIDs market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 27 Analgesics market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 28 DMARDs market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 29 Glucocorticoids market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 30 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
Fig. 31 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
Fig. 32 Prescription market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 33 Over-the-Counter (OTC) market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 34 Rheumatoid arthritis therapeutics market revenue, by region
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 North America rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 37 US country dynamics
Fig. 38 US rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 39 Canada country dynamics
Fig. 40 Canada rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 41 Mexico country dynamics
Fig. 42 Mexico rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 43 Europe rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 44 UK country dynamics
Fig. 45 UK rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 46 Germany country dynamics
Fig. 47 Germany rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 48 France country dynamics
Fig. 49 France rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 50 Italy country dynamics
Fig. 51 Italy rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 52 Spain country dynamics
Fig. 53 Spain rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 54 Norway country dynamics
Fig. 55 Norway rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 56 Sweden country dynamics
Fig. 57 Sweden rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 58 Denmark country dynamics
Fig. 59 Denmark rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 60 Asia Pacific rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 61 Japan country dynamics
Fig. 62 Japan rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 63 China country dynamics
Fig. 64 China rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 65 India country dynamics
Fig. 66 India rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 67 Australia country dynamics
Fig. 68 Australia rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 69 South Korea country dynamics
Fig. 70 South Korea rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 71 Thailand country dynamics
Fig. 72 Thailand rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 73 Latin America rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 74 Brazil country dynamics
Fig. 75 Brazil rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 76 Argentina country dynamics
Fig. 77 Argentina rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 78 MEA rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 79 South Africa country dynamics
Fig. 80 South Africa rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 81 Saudi Arabia country dynamics
Fig. 82 Saudi Arabia rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 83 UAE country dynamics
Fig. 84 UAE rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 85 Kuwait country dynamics
Fig. 86 Kuwait rheumatoid arthritis therapeutics market, 2021 – 2033 (USD Million)
Fig. 87 Company categorization
Fig. 88 Company market position analysis
Fig. 89 Strategic framework
Grand View Researchについて
Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ 1
| シングルユーザ | チーム | エンタープライズ |
| USD 2,950 | USD 3,950 | USD 5,950 |
ライセンスタイプ 2
| シングルユーザ | チーム | エンタープライズ |
| USD 3,950 | USD 4,950 | USD 6,950 |
ライセンスタイプ 3
| シングルユーザ | チーム | エンタープライズ |
| USD 4,950 | USD 5,950 | USD 7,950 |
ライセンスタイプ 4
| シングルユーザ | チーム | エンタープライズ |
| USD 5,950 | USD 6,950 | USD 8,950 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス（インディビジュアルライセンス）
- 1名のみレポートファイル（印刷不可）をご利用いただけます。
- チームライセンス
- 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
- コーポレートライセンス
- 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
- 「関連会社」の範囲についてはお気軽にお問い合わせください。
- シングルユーザライセンス（インディビジュアルライセンス）
- 納品形態
- オンラインダウンロード
- 納期
- ご注文後1～7営業日 ※レポートにより異なります。
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
最新出版レポート